| Heart disease and stroke statistics—2017 update: a report from the American Heart Association EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ... circulation 135 (10), e146-e603, 2017 | 44614* | 2017 |
| ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the … VV McLaughlin, SL Archer, DB Badesch, RJ Barst, HW Farber, JR Lindner, ... Journal of the American college of cardiology 53 (17), 1573-1619, 2009 | 3501 | 2009 |
| 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology … SD Fihn, JM Gardin, J Abrams, K Berra, JC Blankenship, AP Dallas, ... Journal of the American College of Cardiology 60 (24), e44-e164, 2012 | 2452 | 2012 |
| Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American … JS Skyler, R Bergenstal, RO Bonow, J Buse, P Deedwania, EAM Gale, ... Circulation 119 (2), 351-357, 2009 | 2035 | 2009 |
| ACC/AHA/NHLBI clinical advisory on the use and safety of statins RC Pasternak, SC Smith, CN Bairey-Merz, SM Grundy, JI Cleeman, ... Journal of the American College of Cardiology 40 (3), 567-572, 2002 | 1680 | 2002 |
| ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology … Writing Committee Members, DL Bhatt, J Scheiman, NS Abraham, ... Circulation 118 (18), 1894-1909, 2008 | 1581 | 2008 |
| Antiatherothrombotic properties of statins: implications for cardiovascular event reduction RS Rosenson, CC Tangney Jama 279 (20), 1643-1650, 1998 | 1533 | 1998 |
| ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert … WG Hundley, DA Bluemke, JP Finn, SD Flamm, MA Fogel, MG Friedrich, ... Journal of the American College of Cardiology 55 (23), 2614-2662, 2010 | 1243 | 2010 |
| Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport RS Rosenson, HB Brewer Jr, WS Davidson, ZA Fayad, V Fuster, ... Circulation 125 (15), 1905-1919, 2012 | 1093 | 2012 |
| Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19 ATTACC, ACTIV-4a, and REMAP-CAP Investigators New England Journal of Medicine 385 (9), 790-802, 2021 | 880* | 2021 |
| Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and … SM Grundy, GL Vega, ME McGovern, BR Tulloch, DM Kendall, ... Archives of internal medicine 162 (14), 1568-1576, 2002 | 852 | 2002 |
| Dysfunctional HDL and atherosclerotic cardiovascular disease RS Rosenson, HB Brewer Jr, BJ Ansell, P Barter, MJ Chapman, ... Nature reviews cardiology 13 (1), 48-60, 2016 | 808 | 2016 |
| Aspirin for primary prevention of cardiovascular events in people with diabetes American Diabetes Association, American Heart Association, ... Journal of the American College of Cardiology 55 (25), 2878-2886, 2010 | 738 | 2010 |
| Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab E Stroes, D Colquhoun, D Sullivan, F Civeira, RS Rosenson, GF Watts, ... Journal of the American College of Cardiology 63 (23), 2541-2548, 2014 | 717 | 2014 |
| Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel PJ Barter, CM Ballantyne, R Carmena, MC Cabezas, MJ Chapman, ... Journal of internal medicine 259 (3), 247-258, 2006 | 658 | 2006 |
| HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events RS Rosenson, HB Brewer Jr, MJ Chapman, S Fazio, MM Hussain, ... Clinical chemistry 57 (3), 392-410, 2011 | 652 | 2011 |
| Evinacumab for homozygous familial hypercholesterolemia FJ Raal, RS Rosenson, LF Reeskamp, GK Hovingh, JJP Kastelein, ... New England Journal of Medicine 383 (8), 711-720, 2020 | 646 | 2020 |
| The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia JC Fruchart, F Sacks, MP Hermans, G Assmann, WV Brown, R Ceska, ... The American journal of cardiology 102 (10), 1K-34K, 2008 | 620 | 2008 |
| Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial SE Nissen, E Stroes, RE Dent-Acosta, RS Rosenson, SJ Lehman, ... Jama 315 (15), 1580-1590, 2016 | 619 | 2016 |
| An assessment by the statin muscle safety task force: 2014 update RS Rosenson, SK Baker, TA Jacobson, SL Kopecky, BA Parker Journal of clinical lipidology 8 (3), S58-S71, 2014 | 596 | 2014 |
